| 000 | 01762 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250518003800.0 | ||
| 264 | 0 | _c20190822 | |
| 008 | 201908s 0 0 eng d | ||
| 022 | _a1750-7448 | ||
| 024 | 7 |
_a10.2217/imt-2018-0125 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aZhao, Lingdi | |
| 245 | 0 | 0 |
_aCombination of PD-1 blockade and RetroNectin _h[electronic resource] |
| 260 |
_bImmunotherapy _c11 2018 |
||
| 300 |
_a1315-1323 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xtherapeutic use |
| 650 | 0 | 4 |
_aCarcinoma, Non-Small-Cell Lung _ximmunology |
| 650 | 0 | 4 | _aCells, Cultured |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 |
_aCytokine-Induced Killer Cells _ximmunology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFibronectins _ximmunology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunotherapy, Adoptive _xmethods |
| 650 | 0 | 4 |
_aLung Neoplasms _ximmunology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Metastasis |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 |
_aNivolumab _xtherapeutic use |
| 650 | 0 | 4 |
_aProgrammed Cell Death 1 Receptor _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aRecombinant Proteins _ximmunology |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aHan, Lu | |
| 700 | 1 | _aZhang, Yong | |
| 700 | 1 | _aLi, Tiepeng | |
| 700 | 1 | _aYang, Yonghao | |
| 700 | 1 | _aLi, Wei | |
| 700 | 1 | _aShang, Yiman | |
| 700 | 1 | _aLin, Hongwei | |
| 700 | 1 | _aGao, Quanli | |
| 773 | 0 |
_tImmunotherapy _gvol. 10 _gno. 15 _gp. 1315-1323 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2217/imt-2018-0125 _zAvailable from publisher's website |
| 999 |
_c28968217 _d28968217 |
||